Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson’s disease - Fig 3

<p>Three-dimensional graphical representation of the peripapillary choroidal thickness (PPCT) measurements in controls eyes (teaching population in left fig, validating population in middle fig) and Parkinson´s disease (PD) eyes in right fig. Grey, cubes corresponding with the optic nerve head; yellow, PPCT <105 μm; green, mean PPCT ranging from 105 to 139 μm; blue, mean PPCT ranging from 140 to 174 μm; and orange, mean PPCT ≥175 μm.</p

Descriptive, clinical data, choroidal thicknesses and volume for eyes of patients with Parkinson’s disease and from healthy controls (validating population).

<p>Descriptive, clinical data, choroidal thicknesses and volume for eyes of patients with Parkinson’s disease and from healthy controls (validating population).</p

Macular and peripapillary choroidal thickness and volume measured with swept-source deep range imaging optical coherence tomography in patients with Parkinson’s disease and healthy controls.

<p>Macular and peripapillary choroidal thickness and volume measured with swept-source deep range imaging optical coherence tomography in patients with Parkinson’s disease and healthy controls.</p

Comparison of peripapillary choroidal thickness between healthy subjects and patients with Parkinson’s disease - Fig 4

<p>Representation of the mean peripapillary choroidal thickness (PPCT) for the 26×26 cube-grid centered on the optic disc for the three groups: the 40 right healthy eyes of the teaching population (left fig), the 40 right eyes of the healthy validating population (middle fig), and the 40 right eyes of the Parkinson´s disease (PD) patient group (right fig). Grey, cubes corresponding with the optic nerve head; yellow, mean PPCT <105 μm; green, mean PPCT ranging from 105 to 139 μm; blue, mean PPCT ranging from 140 to 174 μm; and orange, mean PPCT ≥175 μm. The temporosuperior choroid is the thickest, followed by superior, temporal, nasal, and inferior choroid.</p

Schematic representation of the 5 zones defined in the 26×26 cube-grid using the peripapillary choroidal thickness measurements in the teaching control population: Zone 1, corresponding with optic nerve head in grey; zone 2 corresponds with mean peripapillary choroidal thickness (PPCT) <105 μm and is represented in yellow; zone 3 corresponds with mean PPCT ranging from 105 to 139 μm, and is represented in green; zone 4 corresponds with mean PPCT ranging from 140 to 174 μm, and is represented in blue; and zone 5 corresponds with mean PPCT ≥175 μm and is represented in orange.

<p>Bottom table: Mean PPCT ± standard deviation of each zone for the three groups evaluated (teaching control group, validating control group, and Parkinson´s disease group).</p

Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with Fibromyalgia syndrome and controls, and statistical significance.

<p>Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with Fibromyalgia syndrome and controls, and statistical significance.</p

Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with early and advantage stages of Fibromyalgia syndrome and statistical significance with controls.

<p>Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with early and advantage stages of Fibromyalgia syndrome and statistical significance with controls.</p

Epidemiologic and disease characteristics of 116 patients with fibromyalgia syndrome and 144 controls included in the study, and statistical significance of the comparisons between the groups (P).

<p>Epidemiologic and disease characteristics of 116 patients with fibromyalgia syndrome and 144 controls included in the study, and statistical significance of the comparisons between the groups (P).</p

Representation and interpretation of the report from the Axonal application of the Spectralis optical coherence tomography in a control (left side) and in a patient with fibromyalgia and retina nerve fiber layer thinning (right side).

<p>Representation and interpretation of the report from the Axonal application of the Spectralis optical coherence tomography in a control (left side) and in a patient with fibromyalgia and retina nerve fiber layer thinning (right side).</p

Bar charts representing optical coherence tomography (OCT) measurements in eyes from 116 fibromyalgia patients and 144 controls.

<p>A- Retinal nerve fiber layer measurements using the ganglion cell layer analysis of Cirrus OCT device. B- Retinal nerve fiber layer measurements using the Glaucoma analytic application of the Spectralis OCT device. C- Retinal nerve fiber layer measurements using the Nsite RNFL Axonal application of the Spectralis OCT device.</p